CN101914065A - 有助于治疗由crth2介导的疾病的嘧啶衍生物 - Google Patents

有助于治疗由crth2介导的疾病的嘧啶衍生物 Download PDF

Info

Publication number
CN101914065A
CN101914065A CN2010101716294A CN201010171629A CN101914065A CN 101914065 A CN101914065 A CN 101914065A CN 2010101716294 A CN2010101716294 A CN 2010101716294A CN 201010171629 A CN201010171629 A CN 201010171629A CN 101914065 A CN101914065 A CN 101914065A
Authority
CN
China
Prior art keywords
amino
benzyl
acetic acid
pyrimidinyl
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010101716294A
Other languages
English (en)
Chinese (zh)
Inventor
T·-W·利
Y·科里亚马
T·尤施诺
H·萨托
K·塔纳卡
H·苏吉莫托
Y·马纳布
K·培根
K·乌尔巴恩斯
M·塞基
T·欣塔尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GB007 Inc
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of CN101914065A publication Critical patent/CN101914065A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2010101716294A 2003-04-25 2004-04-14 有助于治疗由crth2介导的疾病的嘧啶衍生物 Pending CN101914065A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03009384.3 2003-04-25
EP03009384A EP1471057B1 (en) 2003-04-25 2003-04-25 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2004800173378A Division CN1809539B (zh) 2003-04-25 2004-04-14 有助于治疗由crth2介导的疾病的嘧啶衍生物

Publications (1)

Publication Number Publication Date
CN101914065A true CN101914065A (zh) 2010-12-15

Family

ID=32946880

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010101716294A Pending CN101914065A (zh) 2003-04-25 2004-04-14 有助于治疗由crth2介导的疾病的嘧啶衍生物
CN2004800173378A Expired - Fee Related CN1809539B (zh) 2003-04-25 2004-04-14 有助于治疗由crth2介导的疾病的嘧啶衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2004800173378A Expired - Fee Related CN1809539B (zh) 2003-04-25 2004-04-14 有助于治疗由crth2介导的疾病的嘧啶衍生物

Country Status (32)

Country Link
US (2) US7812160B2 (enExample)
EP (2) EP1471057B1 (enExample)
JP (2) JP4671955B2 (enExample)
KR (1) KR101110491B1 (enExample)
CN (2) CN101914065A (enExample)
AR (1) AR043885A1 (enExample)
AT (2) ATE316077T1 (enExample)
AU (1) AU2004233966B2 (enExample)
BR (1) BRPI0409733A (enExample)
CA (1) CA2523439C (enExample)
CL (1) CL43596B (enExample)
CY (1) CY1111295T1 (enExample)
DE (2) DE60303238T2 (enExample)
DK (2) DK1471057T3 (enExample)
DO (1) DOP2004000875A (enExample)
ES (2) ES2257616T3 (enExample)
GT (1) GT200400079A (enExample)
HN (1) HN2004000129A (enExample)
IL (1) IL171566A (enExample)
MX (1) MXPA05011399A (enExample)
MY (1) MY147984A (enExample)
NO (1) NO20055588L (enExample)
NZ (1) NZ543693A (enExample)
PE (1) PE20050143A1 (enExample)
PL (1) PL1633726T3 (enExample)
PT (2) PT1471057E (enExample)
RU (1) RU2361865C2 (enExample)
SI (1) SI1633726T1 (enExample)
TW (1) TWI353980B (enExample)
UY (1) UY28286A1 (enExample)
WO (1) WO2004096777A1 (enExample)
ZA (1) ZA200508722B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
ES2257616T3 (es) 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
DK3718564T3 (da) * 2003-12-23 2023-11-06 Genentech Inc Nye anti-IL-13-antistoffer og anvendelser
US7750014B2 (en) 2004-01-31 2010-07-06 Actimis Pharmaceuticals, Inc. Imidazo[1,2-C]pyrimidinylacetic acid derivatives
AU2005229356B2 (en) 2004-03-11 2011-06-09 Idorsia Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
ATE517085T1 (de) 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
DK1871374T3 (da) 2005-04-21 2011-12-05 Merck Serono Sa 2,3-substituerede pyrazinsulfonamider som CRTH2-inhibitorer
ZA200709819B (en) 2005-05-24 2009-09-30 Serono Lab Tricyclic spiro derivatives as CRTH2 modulators
PE20070589A1 (es) * 2005-10-04 2007-06-22 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
WO2007062677A1 (en) * 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
EA200802415A1 (ru) * 2006-06-09 2009-06-30 Икос Корпорейшн Замещенные фенилуксусные кислоты в качестве dp-2-антагонистов
EP2132196A1 (en) * 2007-02-26 2009-12-16 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
RU2468012C2 (ru) * 2007-06-21 2012-11-27 Актимис Фармасьютикалз, Инк. Частицы антагониста crth2
UA101326C2 (en) 2007-06-21 2013-03-25 Актимис Фармасьютикалз, Инк. Amine salts of crth2 antagonist
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
RU2491279C2 (ru) * 2007-09-25 2013-08-27 Актимис Фармасьютикалз, Инк. 2-s-бензилзамещенные пиримидины в качестве антагонистов crth2
TW200922587A (en) * 2007-09-25 2009-06-01 Actimis Pharmaceuticals Inc Alkylthio pyrimidines as CRTH2 antagonists
US8168678B2 (en) 2008-02-01 2012-05-01 Panmira Pharmaceuticals, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
EP2268611A2 (en) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
MX2010014172A (es) 2008-07-03 2011-02-22 Amira Pharmaceuticals Inc Antagonistas de receptores de prostaglandina d2.
CA2735722A1 (en) * 2008-09-02 2010-03-11 Actimis Pharmaceuticals, Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
AU2009331144A1 (en) 2008-12-25 2011-07-14 Taisho Pharmaceutical Co., Ltd. Isoquinoline derivative
EP2393492A1 (en) * 2009-02-09 2011-12-14 Boehringer Ingelheim International GmbH New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US8273769B2 (en) 2009-02-12 2012-09-25 Merck Serono Sa Phenoxy acetic acid derivatives
WO2010094643A1 (en) * 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
CA2768492A1 (en) 2009-07-31 2011-02-03 Panmira Pharmaceuticals, Llc Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
CN102596902A (zh) 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
US20110294828A1 (en) * 2009-11-24 2011-12-01 Boehringer Ingelheim International Gmbh Process for preparing a polymorph of the choline salt of a pyrimidin-5-yl acetic acid derivative
CA2782085A1 (en) 2010-01-06 2011-07-14 Panmira Pharmaceuticals, Llc Dp2 antagonist and uses thereof
PE20121519A1 (es) 2010-01-27 2012-12-02 Boehringer Ingelheim Int Compuestos de pirazol como antagonistas de crth2
US20130096310A1 (en) 2010-06-23 2013-04-18 Taisho Pharmaceutical Co., Ltd. Isoquinoline derivative
US8575158B2 (en) 2010-07-05 2013-11-05 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
EP2598145A1 (en) 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical composition for treatment of respiratory and inflammatory diseases
WO2012013566A1 (en) 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and inflammatory diseases
BR112013009519A2 (pt) 2010-10-20 2019-10-08 Eng Polymer Solutions Inc método para revestir um container de carga, e, método para fabricação de um container de carga resistente a corrosão
BR112013011737A2 (pt) 2010-11-15 2016-08-09 Univ Leuven Kath composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US8759386B2 (en) 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
JP5999387B2 (ja) 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Crth2拮抗薬としてのピラゾール化合物
JP5988253B2 (ja) 2011-05-16 2016-09-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング [4,6−ビス−ジメチルアミノ−2−[4−(4−トリフルオロメチルベンゾイル−アミノ)ベンジル]ピリミジン−5−イル]酢酸の調製方法
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
BR112014015081A8 (pt) 2011-12-21 2017-06-13 Actelion Pharmaceuticals Ltd derivados heterocíclicos e seu uso como moduladores do receptor d2 de prostaglandina
JP6127135B2 (ja) 2012-07-05 2017-05-10 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 1−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンd2受容体調節剤としてのそれらの使用
US20140148470A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd N―(1h―テトラゾール―5―イル)―2―フェニル―5―ピリミジンカルボキシアミド類及びその合成用中間体
GB9125842D0 (en) 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
US6271238B1 (en) * 1996-09-06 2001-08-07 Nippon Kayaku Kabushiki Kaisha Acetamide derivatives and protease inhibitors
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
WO2001090074A2 (en) * 2000-05-22 2001-11-29 Leo Pharma A/S BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a)
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1413306A1 (en) 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
ES2401079T3 (es) 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
ES2257616T3 (es) 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
UA101326C2 (en) 2007-06-21 2013-03-25 Актимис Фармасьютикалз, Инк. Amine salts of crth2 antagonist
RU2468012C2 (ru) 2007-06-21 2012-11-27 Актимис Фармасьютикалз, Инк. Частицы антагониста crth2

Also Published As

Publication number Publication date
ES2257616T3 (es) 2006-08-01
CA2523439A1 (en) 2004-11-11
CL43596B (es) 2005-03-18
KR20060089622A (ko) 2006-08-09
JP5161290B2 (ja) 2013-03-13
UY28286A1 (es) 2004-11-30
DK1633726T3 (da) 2011-03-28
SI1633726T1 (sl) 2011-04-29
CN1809539A (zh) 2006-07-26
US7960393B2 (en) 2011-06-14
AU2004233966B2 (en) 2010-11-11
HK1095320A1 (en) 2007-05-04
DE602004030907D1 (de) 2011-02-17
ATE316077T1 (de) 2006-02-15
NO20055588L (no) 2006-01-24
NO20055588D0 (no) 2005-11-25
CY1111295T1 (el) 2015-08-05
GT200400079A (es) 2004-11-30
DE60303238T2 (de) 2006-09-14
MXPA05011399A (es) 2006-05-31
JP2006524645A (ja) 2006-11-02
PT1633726E (pt) 2011-02-22
PE20050143A1 (es) 2005-04-01
DE60303238D1 (de) 2006-04-06
EP1471057B1 (en) 2006-01-18
US7812160B2 (en) 2010-10-12
NZ543693A (en) 2009-05-31
HN2004000129A (es) 2009-05-14
PL1633726T3 (pl) 2011-06-30
EP1633726B1 (en) 2011-01-05
DOP2004000875A (es) 2004-10-31
IL171566A (en) 2011-03-31
ZA200508722B (en) 2006-12-27
ES2358424T3 (es) 2011-05-10
BRPI0409733A (pt) 2006-05-09
RU2361865C2 (ru) 2009-07-20
EP1471057A1 (en) 2004-10-27
CN1809539B (zh) 2012-05-09
JP2011068657A (ja) 2011-04-07
TW200505873A (en) 2005-02-16
AU2004233966A1 (en) 2004-11-11
US20100322980A1 (en) 2010-12-23
AR043885A1 (es) 2005-08-17
RU2005136655A (ru) 2006-06-10
PT1471057E (pt) 2006-05-31
ATE494279T1 (de) 2011-01-15
DK1471057T3 (da) 2006-05-15
EP1633726A1 (en) 2006-03-15
JP4671955B2 (ja) 2011-04-20
WO2004096777A1 (en) 2004-11-11
CA2523439C (en) 2012-06-19
MY147984A (en) 2013-02-28
TWI353980B (en) 2011-12-11
US20070129355A1 (en) 2007-06-07
KR101110491B1 (ko) 2012-01-31

Similar Documents

Publication Publication Date Title
CN1809539B (zh) 有助于治疗由crth2介导的疾病的嘧啶衍生物
JP4996257B2 (ja) イミダゾ[1,2−c]ピリミジニル酢酸誘導体
WO2006014482A1 (en) Pyrimidine derivatives useful as inhibitors of pkc-theta
HK1095320B (en) Pyrimidine derivatives useful for the treatment of diseases mediated by crth2

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101215